Palmoplantar WartsNCT07881198
Liquid Nitrogen Cryotherapy Versus CO₂ Laser for Palmoplantar Warts
A study testing Liquid Nitrogen Cryotherapy and Carbon Dioxide (CO₂) Laser Therapy in people with Palmoplantar Warts, run by Bkahtawar Amin Medical and Dental College Multan at 1 site in Pakistan.
Trial summary
This randomized clinical trial will compare the effectiveness of liquid nitrogen cryotherapy and carbon dioxide (CO₂) laser therapy for treating palmoplantar warts, which are human papillomavirus-related skin growths occurring on the palms and soles. Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Palmoplantar Warts
- What is being tested?
- Liquid Nitrogen Cryotherapy and Carbon Dioxide (CO₂) Laser Therapy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 88 participants
- Where
- 1 sitePakistan
- Study dates
- 4 Jun 2026to 3 Dec 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Clinically diagnosed palmoplantar warts
Who cannot join
- Diabetes mellitus
- Peripheral neuropathies
- HIV
- Taking treatment (topical or laser) in last 8 weeks.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan1 site, 1 recruiting
- Recruiting
Bkahtawar Amin Medical and Dental College Multan
Multan, Punjab Province, 60000
Warisha A Principal Investigator, MBBS, +92 333 6050539, warisha.azim96@gmail.com
Muhammad F Associate Professor, FCPS, +92 321 6833118, drfarooq05@yahoo.com
About this study
Official title: Comparison of Efficacy of Liquid Nitrogen Cryotherapy Versus CO2 Laser in Patients With Palmoplantar Warts
This randomized clinical trial will compare the effectiveness of liquid nitrogen cryotherapy and carbon dioxide (CO₂) laser therapy for treating palmoplantar warts, which are human papillomavirus-related skin growths occurring on the palms and soles.
The main question the study aims to answer is:
Read more
- Does CO₂ laser therapy achieve complete wart clearance more frequently than liquid nitrogen cryotherapy after 12 weeks of treatment?
The study will include 88 adults aged 18-50 years with palmoplantar warts. Participants will be randomly assigned to one of two treatment groups:
- Group A: Liquid nitrogen cryotherapy at -196°C, using two freeze-thaw cycles once weekly for up to 8 weeks.
- Group B: CO₂ laser therapy administered weekly for up to 8 weeks.
Participants will be assessed at week 12 after treatment initiation by a consultant dermatologist who will not know which treatment they received. Treatment response will be classified as complete clearance (no remaining warts), partial response (fewer warts than at baseline), or no response (the same or an increased number of warts). The researchers will compare the proportion of participants achieving complete wart clearance between the two groups. Adverse effects, including blistering, ulceration, and infection, will also be recorded during treatment.
- Conditions
- Palmoplantar Warts
- Being tested
- Liquid Nitrogen Cryotherapy, Carbon Dioxide (CO₂) Laser Therapy
- Keywords
- Palmoplantar Warts, Plantar Warts, Palmar Warts, Cryotherapy, Liquid Nitrogen, Carbon Dioxide Laser, CO₂ Laser Therapy, Human Papillomavirus, Wart Clearance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Liquid Nitrogen CryotherapyProcedure or surgery
Participants will be administered using two freeze-thaw cycles once weekly for a maximum of 8 weeks to treat palmoplantar warts.
Carbon Dioxide (CO₂) Laser TherapyProcedure or surgery
Participants will be administered once weekly for a maximum of 8 weeks to treat palmoplantar warts.
| Study group | Role | What they receive |
|---|---|---|
| Liquid Nitrogen Cryotherapy | Active comparator | Participants will receive liquid nitrogen cryotherapy at -196°C Receives: Procedure: Liquid Nitrogen Cryotherapy |
| CO₂ Laser Therapy | Experimental | Participants will receive carbon dioxide (CO₂) laser therapy Receives: Procedure: Carbon Dioxide (CO₂) Laser Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Treatment Efficacy
Proportion of participants achieving complete clearance of palmoplantar warts, defined as the absence of any wart lesions at the 12-week assessment compared with baseline.
Measured: From enrollment through the final assessment at 12-weeks (including 8 weeks of treatment)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Oct 2026
- Study start4 Jun 2026
- Primary completion3 Dec 2026 (estimated)
- Study completion3 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Palmoplantar WartsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 88 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bkahtawar Amin Medical and Dental College Multan
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Warisha Azam Khan, Bkahtawar Amin Medical and Dental College Multan
- Investigators
- Muhammad F Associate Professor, FCPS, Study chair, Bkahtawar Amin Medical and Dental College Multan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07881198
- Sponsor's protocol ID
- U1111-1348-1366
- Status last verified
- Oct 2026
- First submitted
- 12 Oct 2026
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No